<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04108325</url>
  </required_header>
  <id_info>
    <org_study_id>YY-20394-004</org_study_id>
    <nct_id>NCT04108325</nct_id>
  </id_info>
  <brief_title>A Phase Ib Study of YY-20394 in Patients With Recurrent or Refractory Peripheral T-Cell Lymphoma</brief_title>
  <official_title>A Single-Arm, Open-Label, Multi-Center, Phase I Study of YY-20394 in Patients With Recurrent or Refractory Peripheral T-Cell Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai YingLi Pharmaceutical Co. Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai YingLi Pharmaceutical Co. Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study YY-20394-004 is a phase I single arm, open label study. The primary objective is to
      assess the safety and efficacy of YY-20394 in subjects with Recurrent or Refractory
      Peripheral T-Cell Lymphoma.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2019</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">June 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse events evaluated by NCI CTCAE v5.0</measure>
    <time_frame>2 years</time_frame>
    <description>Incidence of adverse events of YY-20394</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Objective response rate</measure>
    <time_frame>with in 56 days after the first dos</time_frame>
    <description>Response will be determined by Response evaluation criteria in solid tumours; v1.1</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">58</enrollment>
  <condition>Recurrent or Refractory Peripheral T-Cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>YY-20394</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>YY-20394 tablets will be given daily for 28 days in 28-day cycles until there appears evidence of progressive disease, intolerable toxicity, or the subject discontinues from the study treatment for other reasons.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>YY-20394</intervention_name>
    <description>YY-20394 tablets will be given daily for 28 days in 28-day cycles until there appears evidence of progressive disease, intolerable toxicity, or the subject discontinues from the study treatment for other reasons.</description>
    <arm_group_label>YY-20394</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Males and/or females over age 18

          2. Histologically or cytologically confirmed advanced solid tumors. Failure or lack of
             standard treatment.

          3. Eastern Cooperative Oncology Group performance status of 0 to 2

          4. Life expectancy of at least 3 months

          5. At least one measurable lesion according to RECIST1.1.

          6. Acceptable hematologic status:

             Absolute neutrophil count(ANC)≥1.5×10^9/L; Platelet count(PLT)≥75×10^9/L;
             Hemoglobin(Hb)≥80 g/L; Total bilirubin(TBIL)≤1.5×Upper limit of normal value(ULN);
             Alanine aminotransferase(ALT)≤1.5×ULN; Aspartate aminotransferase(AST)≤1.5×ULN;
             Creatinine(Cr)≤1.5×ULN; Left Ventricular Ejection Fractions(LVEF)≥50%# QTcF#male#450
             ms,female #470 ms

          7. Accept to use proper contraceptives throughout the study period and within 6 months
             after the last dose.

          8. Ability to respect the protocol approved by investigator.

          9. Ability to understand and the willingness to sign a written informed consent document.

        Exclusion Criteria:

          1. Previously treated with PI3Kδ inhibitors and cause disease progression (removed from
             the study because of intolerance is not included).

          2. Any anti-tumor treatment, within 4 weeks prior to study entry, such as chemotherapy,
             radiotherapy and immunotherapy. Nitrosoureas or mitomycin C within 6 weeks prior to
             study entry. Oral drug of fluorouracil or small molecular targeted drugs 2 weeks prior
             to study entry.

          3. Any other investigational agents within 4 weeks prior to study entry.

          4. Any surgery on main organ (needle biopsy not included) or serious injury within 4
             weeks prior to study entry. Selective operation is required during the study period.

          5. Adverse events of previous anti-cancer treatment have not recovered to CTCAE v5.0 ≤1.

          6. There are third interstitial effusions (such as massive pleural effusion and ascites)
             which can not be controlled by drainage or other methods.

          7. The dosage of steroid hormone (prednisone equivalent) was greater than 20mg/day, and
             lasted for more than 14 days.

          8. Medical history of difficulty in swallowing, malabsorption, or other chronic
             gastrointestinal disease, or conditions that may hamper compliance and/ or absorption
             of the tested drug.

          9. During the study period, drugs that may prolong the QT (such as anti arrhythmic drugs)
             could not be interrupted.

         10. Patients with central nervous system (CNS) matastasis or meningeal metastasis with
             clinical symptoms, or there are evidences of CNS matastasis or meningeal metastasis
             uncontrolled approved by investigators.

         11. Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic
             therapy(such as pneumonia).

         12. Active hepatitis b (HBV titers#1000 copies/ml or 200IU/ml), prophylactic antiviral
             therapies other than interferon are allowed. Patients with Hepatitis C virus
             (hepatitis C antibody test positive).

         13. History of immunodeficiency, including HIV positive test, other acquired or congenital
             immunodeficiency disorders, organ transplantation or allogeneic bone marrow
             transplantation.

         14. Has suffered from any heart disease within 6 months prior to study entry, including:
             (1) angina pectoris; (2) medicated or clinically significant arrhythmia; (3)
             myocardial infarction; (4) heart failure; (5) any other heart disease judged by the
             researchers not suitable for the test.

         15. The baseline pregnancy test was positive in pregnant women, lactating women or fertile
             women.

         16. According to the judgement of the investigator, there are concomitant diseases that
             seriously endanger the safety of patients or affect the completion of the study (such
             as severe hypertension, diabetes, thyroid diseases, etc.

         17. Patients suffering from other primary malignant tumors in the past 5 years. Patients
             with curable local tumors (such as basal or squamous cell carcinoma, superficial
             bladder cancer, carcinoma in situ of the cervix or of the breast) could be enrolled
             after completely cured.

             -
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Qiu Lugui, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institute of Hematology, Chinese Academy of Medical Science</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bao Hanying, PhD</last_name>
    <phone>86 21-5137069</phone>
    <email>hybao@yl-pharma.com</email>
  </overall_contact>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>September 26, 2019</study_first_submitted>
  <study_first_submitted_qc>September 27, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 30, 2019</study_first_posted>
  <last_update_submitted>September 27, 2019</last_update_submitted>
  <last_update_submitted_qc>September 27, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 30, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, T-Cell</mesh_term>
    <mesh_term>Lymphoma, T-Cell, Peripheral</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

